A cell-cycle independent role for p21 in regulating synovial fibroblast migration in rheumatoid arthritis

Arthritis Research and Therapy

Volumn 8, Issue 4, 2006, Pages

  Woods, James M ^a   Klosowska, Karolina ^a   Spoden, Darrin J ^a   Stumbo, Nataliya G ^a   Paige, Douglas J ^a   Scatizzi, John C ^b   Volin, Michael V ^a   Rao, Malathi S ^a   Perlman, Harris ^b  

^a MIDWESTERN UNIVERSITY   (United States)

^b SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR 1A; FIBROBLAST GROWTH FACTOR 2;

ANIMAL; CELL CYCLE; CELL DIVISION; CELL MOTION; CHEMOTAXIS; DEFICIENCY; DRUG EFFECTS; FIBROBLAST; HUMAN; KNOCKOUT MOUSE; METABOLISM; MOUSE; PATHOLOGY; PATHOPHYSIOLOGY; RHEUMATOID ARTHRITIS; SYNOVIAL FLUID; SYNOVIUM;

ANIMALS; ARTHRITIS, RHEUMATOID; CELL CYCLE; CELL DIVISION; CELL MOVEMENT; CHEMOTAXIS; CYCLIN-DEPENDENT KINASE INHIBITOR P21; FIBROBLAST GROWTH FACTOR 2; FIBROBLASTS; HUMANS; MICE; MICE, KNOCKOUT; SYNOVIAL FLUID; SYNOVIAL MEMBRANE;

EID: 34547869352     PISSN: 14786354     EISSN: 14786362     Source Type: Journal    
DOI: 10.1186/ar1999     Document Type: Article

References (34)

1. Sherr CJ: Cancer cell cycles. Science 1996, 274 1672-1677.
2. Nasmyth P: Viewpoint: putting the cell cycle in order. Science 1996, 274:1643-1645.
3. Gao CY, Zelenka PS: Cyclins, cyclin-dependent kinases and differentiation. Bioessays 1997, 19:307-315.
4. Krimpenfort P, Quon KC, Mooi WJ, Loonstra A, Berns A: Loss of p16Ink4a confers susceptibility to metastatic melanoma in mice. Nature 2001, 413:83-86.
5. Sharpless NE, Bardeesy N, Lee KH, Carrasco D, Castrillon DH, Aguirre AJ, Wu EA, Horner JW, DePinho RA: Loss of p16Ink4a with retention of p19Arf predisposes mice to tumorigenesis. Nature 2001, 413 86-91.
6. Franklin DS, Godfrey VL, Lee H, Kovalev GI, Schoonhoven R, Chen-Kiang S, Su L, Xiong Y: CDK inhibitors p18(INK4c) and p27(Kip1) mediate two separate pathways to collaboratively suppress pituitary tumorigenesis Genes Dev 1998, 12:2899-2911.
7. Kamijo T, Bodner S, van de Kamp E, Randle DH, Sherr CJ: Tumor spectrum in ARF-deficient mice. Cancer Res 1999, 59 2217-2222.
8. Kamijo T, Zindy F, Roussel MF, Quelle DE, Downing JR, Ashmun RA, Grosveld G, Sherr CJ: Tumor suppression at the mouse INK4a locus mediated by the alternative reading frame product p19ARF. Cell 1997, 91:649-659.
9. Park MS, Rosai J, Nguyen HT, Capodieci P, Cordon-Cardo C, Koff A: p27 and Rb are on overlapping pathways suppressing tumorigenesis in mice. Proc Natl Acad Sci USA 1999, 96:6382-6387.
10. Nakayama K, Ishida N, Shirane M, Inomata A, Inoue T, Shishido N, Horii I, Loh DY, Nakayama K-I: Mice lacking p27Kip1 display increased body size, multiple organ hyperplasia, retinal dysphasia, and pituitary tumors. Cell 1996, 85:707-720.
11. Fero ML, Rivkin M, Tasch M, Porter P, Carow CE, Firpo E, Polyak K, Tsai L-H, Broudy V, Perlmutter RM, et al.: A syndrom of multiorgan hyperplasia with features of gigantism, tumorigenesis, and female sterility in p27Kip1-deficient mice. Cell 1996, 85 733-744.
12. Brugarolas J, Bronson RT, Jacks T: p21 is a critical CDK2 regulator essential for proliferation control in Rb-deficient cells. J Cell Biol 1998, 141:503-514.
13. Martin-Caballero J, Flores JM, Garcia-Palencia P, Serrano M: Tumor susceptibility of p21(Waf1/Cip1)-deficient mice. Cancer Res 2001, 61:6234-6238.
14. Balomenos D, Martin-Caballero J, Garcia MI, Prieto I, Flores JM, Serrano M, Martinez AC: The cell cycle inhibitor p21 controls Tcell proliferation and sex-linked lupus development. Nat Med 2000, 6:171-176.
15. Salvador JM, Hollander MC, Nguyen AT, Kopp JB, Barisoni L, Moore JK, Ashwell JD, Fornace AJ Jr: Mice lacking the p53-effector gene Gadd45a develop a lupus-like syndrome. Immunity 2002, 16:499-508.
16. Coqueret O: New roles for p21 and p27 cell-Aycle inhibitors: a function for each cell compartment? Trends Cell Biol 2003, 13:65-70.
17. Besson A, Gurian-West M, Schmidt A, Hall A, Roberts JM: p27Kip1 modulates cell migration through the regulation of RhoA activation. Genes Dev 2004, 18:862-876.
18. Choy EH, Panayi GS: Cytokine pathways and joint inflammation in rheumatoid arthritis. N Engl J Med 2001, 344:907-916.
19. Lehmann J, Jungel A, Lehmann I, Busse F, Biskop M, Saalbach A, Emmrich F, Sack U: Grafting of fibroblasts isolated from the synovial membrane of rheumatoid arthritis (RA) patients induces chronic arthritis in SCID mice-A novel model for studying the arthritogenic role of RA fibroblasts in vivo. J Autoimmun 2000, 15:301-313.
20. Perlman H, Bradley K, Liu H, Cole S, Shamiyeh E, Smith RC, Walsh K, Fiore S, Koch AE, Firestein GS, et al.: IL-6 and matrix metalloproteinase-1 are regulated by the cyclin-dependent kinase inhibitor p21 in synovial fibroblasts. J Immunol 2003, 170 838-845.
21. Nasu K, Kohsaka H, Nonomura Y, Terada Y, Ito H, Hirokawa K, Miyasaka N: Adenoviral transfer of cyclin-dependent kinase inhibitor genes suppresses collagen-induced arthritis in mice. J Immunol 2000, 165:7246-7252.
22. Nonomura Y, Kohsaka H, Nagasaka K, Miyasaka N: Gene transfer of a cell cycle modulator exerts anti-inflammatory effects in the treatment of arthritis. J Immunol 2003, 171:4913-4919.
23. Nonomura Y, Kohsaka H, Nasu K, Terada Y, Ikeda M, Miyasaka N: Suppression of arthritis by forced expression of cyclindependent kinase inhibitor p21(Cip1) gene into the joints. Int Immunol 2001, 13:723-731.
24. Taniguchi K, Kohsaka H, Inoue N, Terada Y, Ito H, Hirokawa K, Miyasaka N: Induction of the p16INK4a senescence gene as a new therapeutic strategy for the treatment of rheumatoid arthritis. Nat Med 1999, 5:760-767.
25. Yamanishi Y, Boyle DL, Pinkoski MJ, Mahboubi A, Lin T, Han Z, Zvaifler NJ, Green DR, Firestein GS: Regulation of joint destruction and inflammation by p53 in collagen-induced arthritis. Am J Pathol 2002, 160:123-130.
26. Han Z, Boyle DL, Chang L, Bennett B, Karin M, Yang L, Manning AM, Firestein GS: c-Jun N-terminal kinase is required for metalloproteinase expression and joint destruction in inflammatory arthritis. J Clin Invest 2001, 108:73-81.
27. Wang AZ, Chen JM, Fisher GW, Wang JC, Diamond HS: Improved in vitro models for assay of rheumatoid synoviocyte chemotaxis. Clin Exp Rheumatol 1994, 12:293-299.
28. al-Mughales J, Blyth TH, Hunter JA, Wilkinson PC: The chemoattractant activity of rheumatoid synovial fluid for human lymphocytes is due to multiple cytokines. Clin Exp Immunol 1996, 106:230-236.
29. Volin MV, Woods JM, Amin MA, Connors MA, Harlow LA, Koch AE: Fractalkine: A novel angiogenic chemokine in rheumatoid arthritis. Am J Pathol 2001, 159:1521-1530.
30. Shiozawa S, Shiozawa K, Fujita T: Morphologic observations in the early phase of the cartilage-pannus junction. Light and electron microscopic studies of active cellular pannus. Arthritis Rheum 1983, 26:472-478.
31. Witzenbichler B, Kureishi Y, Luo Z, Le Roux A, Branellec D, Walsh K: Regulation of smooth muscle cell migration and integrin expression by the Gax transcription factor. J Clin Invest 1999, 104 1469-1480.
32. Smith RC, Branellec D, Gorski DH, Guo K, Perlman H, Dedieu JF, Pastore C, Mahfoudi A, Denefle P, Isner JM, et al.: p21CIP1-mediated inhibition of cell proliferation by overexpression of the gax homeodomain gene. Genes Dev 1997, 11:1674-1689.
33. Firestein GS: Invasive fibroblast-like synoviocytes in rheumatoid arthritis. Passive responders or transformed aggressors? Arthritis Rheum 1996, 39:1781-1790.
34. Tolboom TC, van der Helm-Van Mil AH, Nelissen RG, Breedveld FC, Toes RE, Huizinga TW: Invasiveness of fibroblast-like synoviocytes is an individual patient characteristic associated with the rate of joint destruction in patients with rheumatoid arthritis. Arthritis Rheum 2005, 52:1999-2002.